Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
After finishing at $65.57 in the prior trading day, Cytokinetics Inc (NASDAQ: CYTK) closed at $66.82, up 1.91%. In other words, the price has increased by $1.91 from its previous closing price. On the day, 0.78 million shares were traded. CYTK stock price reached its highest trading level at $67.45 during the session, while it also had its lowest trading level at $65.68.
Ratios:
Our goal is to gain a better understanding of CYTK by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.12 and its Current Ratio is at 6.12.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, UBS on January 24, 2024, Downgraded its rating to Neutral and sets its target price to $92 from $61 previously.
On January 05, 2024, Morgan Stanley Downgraded its rating to Equal-Weight which previously was Overweight and also upped its target price recommendation from $60 to $90.
On November 09, 2023, Goldman started tracking the stock assigning a Buy rating and target price of $50.Goldman initiated its Buy rating on November 09, 2023, with a $50 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Apr 09 ’24 when Malik Fady Ibraham sold 32,605 shares for $74.31 per share. The transaction valued at 2,422,918 led to the insider holds 138,567 shares of the business.
Malik Fady Ibraham sold 32,604 shares of CYTK for $2,202,606 on Mar 05 ’24. The EVP Research & Development now owns 138,973 shares after completing the transaction at $67.56 per share. On Feb 14 ’24, another insider, HENDERSON JOHN T, who serves as the Director of the company, sold 5,000 shares for $76.48 each. As a result, the insider received 382,400 and left with 42,632 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CYTK now has a Market Capitalization of 6987768320 and an Enterprise Value of 7024864768. For the stock, the TTM Price-to-Sale (P/S) ratio is 928.03. Its current Enterprise Value per Revenue stands at 932.917 whereas that against EBITDA is -14.505.
Stock Price History:
Over the past 52 weeks, CYTK has reached a high of $110.25, while it has fallen to a 52-week low of $25.98. The 50-Day Moving Average of the stock is -5.61%, while the 200-Day Moving Average is calculated to be 31.55%.
Shares Statistics:
The stock has traded on average 2.06M shares per day over the past 3-months and 1116690 shares per day over the last 10 days, according to various share statistics. A total of 101.64M shares are outstanding, with a floating share count of 100.94M. Insiders hold about 3.48% of the company’s shares, while institutions hold 108.17% stake in the company. Shares short for CYTK as of 1711584000 were 13228799 with a Short Ratio of 6.41, compared to 1709164800 on 14533443. Therefore, it implies a Short% of Shares Outstanding of 13228799 and a Short% of Float of 20.7.
Earnings Estimates
The stock of Cytokinetics Inc (CYTK) is currently being evaluated by 15.0 analysts who are actively contributing to its market rating.On average, analysts expect EPS of -$1.14 for the current quarter, with a high estimate of -$0.89 and a low estimate of -$1.35, while EPS last year was -$1.38. The consensus estimate for the next quarter is -$1.12, with high estimates of -$0.82 and low estimates of -$1.36.
Analysts are recommending an EPS of between -$3.43 and -$5.42 for the fiscal current year, implying an average EPS of -$4.45. EPS for the following year is -$3.29, with 15.0 analysts recommending between -$1.53 and -$5.0.
Revenue Estimates
Based on 15 analysts’ estimates, the company’s revenue will be $144.98M in the next fiscal year. The high estimate is $394.65M and the low estimate is $5M.
